Haemodynamics stability in liver transplant recipients.

Effect of isoflurane and Target control infusion (TCI) Propofol on intra-operative usage of vasopressors in liver transplant recipients: A randomized controlled trial. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/065647

Enrollment

Registered

2024-04-15

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Propofol: Dose: TCI infusion system with target plasma concentration starting 2.5 mcg/ml. Frequency: Throughout intraoperative Route: intravenous Duration: till the surgery over Contro

Eligibility

Inclusion criteria

Inclusion criteria: –Above 18 years of age who will undergo living donor liver transplant

Exclusion criteria

Exclusion criteria: 1. Refusal to consent 2. Acute liver failure, Acute on chronic liver failure 3. Allergic to propofol or any component of propofol 4. Patients with pre existing cardiac dysfunction and cardiomyopathy 5. Patients with pre existing renal dysfunction/ deranged RFTs preoperatively

Design outcomes

Primary

Measure	Time frame
Comparison of total Noradrenaline and vasopressin requirement between isoflurane and TCI propofol group in Living donor liver transplant recipients intraoperatively Timepoint: Intraoperatively	—

Secondary

Measure	Time frame
Peak dose of nordrenaline and vasopressin during different phases of liver transplant intraoperatively Timepoint: Intraoperatively;Peak lactate levels intraoperatively Timepoint: Intraoperatively;Postoperative coagulation profile at 12, 24, 72 hours and day 7 Timepoint: 12,24,72 hours and day 7;Postoperative Liver function tests ie Bilirubin, AST, ALT, GGT, albumin, platelet count at 12, 24, 72 hours and day 7 Timepoint: 12,24,72 hours and day 7;Postoperative Renal function tests i.e. Blood urea and S.creatinine levels at12, 24, 72 hrs and POD 7Timepoint: 12, 24, 72 hrs and POD 7;QTc interval between the two groups during different phases of liver transplant measured every 15 minutes Timepoint: Intraoperatively;To compare between the two groups mean arterial pressure,systemic vascular resistance and cardiac output during different phases of liver transplant recorded every 15 minutes Timepoint: Intraoperatively and 0,12,24,72 hours and day 7 postoperatively;Total vasopressor requirement during reperfusion Timepoint: Intraoperatively	—

Measure

Time frame

Peak dose of nordrenaline and vasopressin during different phases of liver transplant intraoperatively Timepoint: Intraoperatively;Peak lactate levels intraoperatively Timepoint: Intraoperatively;Postoperative coagulation profile at 12, 24, 72 hours and day 7 Timepoint: 12,24,72 hours and day 7;Postoperative Liver function tests ie Bilirubin, AST, ALT, GGT, albumin, platelet count at 12, 24, 72 hours and day 7 Timepoint: 12,24,72 hours and day 7;Postoperative Renal function tests i.e. Blood urea and S.creatinine levels at12, 24, 72 hrs and POD 7Timepoint: 12, 24, 72 hrs and POD 7;QTc interval between the two groups during different phases of liver transplant measured every 15 minutes Timepoint: Intraoperatively;To compare between the two groups mean arterial pressure,systemic vascular resistance and cardiac output during different phases of liver transplant recorded every 15 minutes Timepoint: Intraoperatively and 0,12,24,72 hours and day 7 postoperatively;Total vasopressor requirement during reperfusion Timepoint: Intraoperatively

—

Countries

India

Contacts

Public ContactDr Deepak Kumar Tempe

Institute of Liver and Biliary Sciences

tempedeepak@hotmail.com01146300000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026